HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

ESCRIBER	R	PATIENT:
me:		Name:
rd:		NHI:
propterin	n dihydrochloride	
	ent required after 1 month s (tick boxes where appropriate)	
	scribed by, or recommended by a metabolic physiciar Hospital.	n, or in accordance with a protocol or guideline that has been endorsed by the Health
and	Patient has phenylketonuria (PKU) and is pregnant	t or actively planning to become pregnant
and	Treatment with sapropterin is required to support m	nanagement of PKU during pregnancy
and	Sapropterin to be administered at doses no greater	r than a total daily dose of 20 mg/kg
and	Sapropterin to be used alone or in combination with	h PKU dietary management
	Total treatment duration with sapropterin will not ex	cceed 22 months for each pregnancy (includes time for planning and becoming
erequisites	ent required after 12 months s (tick boxes where appropriate)	
-assessmer erequisites Presi	PION ent required after 12 months s (tick boxes where appropriate) scribed by, or recommended by a metabolic physician Hospital.	n, or in accordance with a protocol or guideline that has been endorsed by the Health
erequisites Prese	PON ent required after 12 months s (tick boxes where appropriate) scribed by, or recommended by a metabolic physician Hospital. Following the initial one-month approval, the sapropterin with a clinically appropriate reducer On subsequent renewal applications, the patential one-month approval is the sapropriate reducer.	patient has demonstrated an adequate response to a 2 to 4 week trial of ction in phenylalanine levels to support management of PKU during pregnancy tient has previously demonstrated response to treatment with sapropterin and
erassessmer erequisites Press NZ H	PON ent required after 12 months s (tick boxes where appropriate) scribed by, or recommended by a metabolic physician Hospital. Following the initial one-month approval, the sapropterin with a clinically appropriate reducer On subsequent renewal applications, the patential one-month approval is the sapropriate reducer.	n, or in accordance with a protocol or guideline that has been endorsed by the Health patient has demonstrated an adequate response to a 2 to 4 week trial of ction in phenylalanine levels to support management of PKU during pregnancy
-assessmer erequisites O Press NZ H	Pont required after 12 months solved tick boxes where appropriate) scribed by, or recommended by a metabolic physician Hospital. Following the initial one-month approval, the sapropterin with a clinically appropriate reduction. On subsequent renewal applications, the pat maintained adequate phenylalanine levels to Patient continues to be pregnant and treatment.	patient has demonstrated an adequate response to a 2 to 4 week trial of ction in phenylalanine levels to support management of PKU during pregnancy tient has previously demonstrated response to treatment with sapropterin and
or-assessmer erequisites O Press NZ H or and	Pont required after 12 months is (tick boxes where appropriate) scribed by, or recommended by a metabolic physician Hospital. Following the initial one-month approval, the sapropterin with a clinically appropriate reduce of the sapropterin with a clinically appropriate reduced of the sapropterin is required for a sapropterin with sapropterin wit	patient has demonstrated an adequate response to a 2 to 4 week trial of ction in phenylalanine levels to support management of PKU during pregnancy tient has previously demonstrated response to treatment with sapropterin and support management of PKU during pregnancy
orassessmer erequisites O Press NZ H or and or	Pont required after 12 months set (tick boxes where appropriate) scribed by, or recommended by a metabolic physician Hospital. Following the initial one-month approval, the sapropterin with a clinically appropriate reduce of the sapropterin with a clinically appropriate reduced of the sapropterin is required for a sapregnancy.	patient has demonstrated an adequate response to a 2 to 4 week trial of ction in phenylalanine levels to support management of PKU during pregnancy tient has previously demonstrated response to treatment with sapropterin and support management of PKU during pregnancy this is the first renewal for treatment with sapropterin second or subsequent pregnancy to support management of their PKU during
or and or or	Pont required after 12 months is (tick boxes where appropriate) scribed by, or recommended by a metabolic physician Hospital. Following the initial one-month approval, the sapropterin with a clinically appropriate reduce of the sapropterin with a clinically appropriate reduced of the sapropterin is required for a sapropterin with sapropterin wit	patient has demonstrated an adequate response to a 2 to 4 week trial of ction in phenylalanine levels to support management of PKU during pregnancy tient has previously demonstrated response to treatment with sapropterin and support management of PKU during pregnancy ent with sapropterin will not continue after delivery this is the first renewal for treatment with sapropterin second or subsequent pregnancy to support management of their PKU during